Apnimed has filed a notice of an exempt offering of securities to raise $23 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Apnimed is raising up to $23,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Apnimed
Apnimed is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, dedicated to transforming the treatment landscape for sleep-related breathing diseases through innovative oral therapies. The company’s primary focus is on developing pharmacologic solutions for obstructive sleep apnea (OSA), a common and serious sleep disorder. Apnimed’s lead candidate, AD109, is an investigational, first-in-class oral medication designed to be taken once daily at bedtime, targeting the neurological control of upper airway muscles to maintain an open airway during sleep. Having announced positive topline results from two pivotal Phase 3 clinical trials for AD109, Apnimed aims to provide a simple, safe, and effective pharmaceutical alternative to current mechanical treatments like CPAP devices, with plans to submit a New Drug Application to the U.S. FDA by early 2026.
To learn more about Apnimed, visit https://apnimed.com/
Apnimed Linkedin Page: https://www.linkedin.com/company/apnimed/
Contact:
Lawrence Miller, Chief Executive Officer
617-500-8880
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
